---
title: "Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick Austin"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293603665.md"
description: "Veraxa Biotech has appointed Christoph Erkel as its new Chief Scientific Officer, effective immediately. He succeeds Rick Austin, who will exit the company after a transition period. Erkel brings 20 years of experience in antibody therapeutics and previously led immuno-oncology programs at MorphoSys. His role involves driving the development of Veraxa's BiTAC platform and oncology pipeline."
datetime: "2026-07-23T11:02:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293603665.md)
  - [en](https://longbridge.com/en/news/293603665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293603665.md)
generator: "portal-rs"
---

# Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick Austin

-   Veraxa Biotech named Christoph Erkel chief scientific officer, effective immediately, to drive development of its BiTAC platform and oncology pipeline. \* Erkel was previously vice president of R&D; his background includes 20 years in antibody therapeutics spanning discovery through IND submission. \* He previously led immuno-oncology programs at MorphoSys, including conditionally active T-cell engagers, following roles at Sloning BioTechnology. \* Rick Austin will exit the company following a transition period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230700OMX\_\_\_\_\_CNEWS\_EN\_GNW1001214113\_en) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [MOR.DE](https://longbridge.com/en/quote/MOR.DE.md)

## Related News & Research

- [Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650](https://longbridge.com/en/news/297556855.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [PC Gold appoints Rick Clark, Matthew Scully as non-executive directors](https://longbridge.com/en/news/297182368.md)
- [Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with Secarna](https://longbridge.com/en/news/296781575.md)
- [VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision](https://longbridge.com/en/news/296815081.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**